Table 2. Univariate and multivariate analyses of factors associated with overall survival, progression-free survival, and pneumonitis-free survival.
Variables | UVA | MVA | |||
---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | ||
Overall survival and factors associated | |||||
Age, years | 0.963 (0.89–1.04) | 0.34 | |||
Race | |||||
White | Ref | ||||
Black or African-American | 2.44 (0.27–22.2) | 0.43 | |||
Other | 0 | 0.99 | |||
Smoking status | |||||
Current smoker | Ref | ||||
Former smoker | 0.61 (0.07–5.61) | 0.663 | |||
Never smoker | 0 | 0.989 | |||
Stage | |||||
IIIA | Ref | ||||
IIIB | 0.92 (0.15–5.63) | 0.93 | |||
Other | 0 | 0.99 | |||
Histology | |||||
Adenocarcinoma | Ref | ||||
Squamous | 2.04 (0.13–32.9) | 0.62 | |||
Non-small cell, NOS | 4.45 (0.46–42.9) | 0.2 | |||
Total lung-PTV V5 | 0.98 (0.92–1.04) | 0.52 | |||
Total lung-PTV V20 | 0.95 (0.85–1.06) | 0.36 | |||
Total lung mean | 0.89 (0.72–1.1) | 0.29 | |||
Heart V50 | 0.96 (0.82–1.13) | 0.65 | |||
Number of durvalumab cycles delivered | 0.88 (0.77–1.01) | 0.64 | |||
Charlson/Deyo Comorbidity Score | 0.88 (0.58–1.33) | 0.54 | |||
Progression-free survival and factors associated | |||||
Age, years | 0.932 (0.88–0.98) | 0.011** | NS | ||
Race | |||||
White | Ref | ||||
Black or African-American | 0.49 (0.06–4.00) | 0.51 | |||
Other | 0.98 (0.12–7.78) | 0.98 | |||
Smoking status | |||||
Current smoker | Ref | ||||
Former smoker | 0.34 (0.07–1.70) | 0.19 | |||
Never smoker | 0.54 (0.07–4.08) | 0.55 | |||
Stage | |||||
IIIA | Ref | ||||
IIIB | 0.51 (0.14–1.90) | 0.32 | |||
Other | 0 | 0.98 | |||
Histology | |||||
Adenocarcinoma | Ref | ||||
Squamous | 1.44 (0.29–7.3) | 0.66 | |||
Non-small cell, NOS | 3.83 (0.91–16.1) | 0.07 | |||
Number of durvalumab cycles delivered | 0.89 (0.82–0.96) | 0.002** | 0.89 (0.82–0.96) | 0.003** | |
Charlson/Deyo comorbidity score | 0.58 (0.39–0.86) | 0.006** | 0.55 (0.36–0.86) | 0.01** | |
Pneumonitis-free survival and factors associated | |||||
Age, years | 1.05 (0.98–1.13) | 0.16 | |||
Smoking status | |||||
Current smoker | Ref | ||||
Former smoker | 0.61 (0.08–4.94) | 0.65 | |||
Never smoker | 0.39 (0.02–4.66) | 0.38 | |||
Stage | |||||
IIIA | Ref | ||||
IIIB | 0.46 (0.09–2.17) | 0.33 | |||
Other | 0 | 0.98 | |||
Histology | |||||
Adenocarcinoma | Ref | ||||
Squamous | 0.92 (0.26–3.25) | 0.89 | |||
Non-small cell, NOS | 0 | 0.98 | |||
Total lung-PTV V5 | 0.95 (0.90–0.99) | 0.03** | |||
Total lung-PTV V20 | 0.96 (0.88–1.05) | 0.39 | |||
Total lung mean | 0.90 (0.76–1.06) | 0.21 | |||
Number of durvalumab cycles delivered | 0.92 (0.82–1.03) | 0.14 | |||
Charlson/Deyo comorbidity score | 1.08 (0.86–1.37) | 0.51 |
No factors were associated with overall survival. The number of durvalumab cycles delivered and comorbidity score were significantly associated with progression free survival on multivariate analysis. Lung V5 was significantly associated with pneumonitis on univariate. ** denotes statistical significance. UVA, univariate; MVA, multivariate; OS, overall survival; PFS, progression free survival; NOS, not otherwise specified; NS, not significant; HR, hazard ratio; CI, confidence interval.